

Marta Schirripa

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1588775/marta-schirripa-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264
papers

16,400
citations

53
h-index

125
g-index

300
ext. papers

20,267
ext. citations

7.4
avg, IF

6.42
L-index

#	Paper	IF	Citations
264	LRP1B and GRM3 expression in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 177-177	2.2	
263	A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 100-100	2.2	0
262	Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 246-246	2.2	
261	Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. <i>International Journal of Cancer</i> , 2022 , 150, 279-289	7.5	1
260	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.. <i>JAMA Network Open</i> , 2022 , 5, e2149040	18.4	4
259	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. <i>Oncogene</i> , 2021 ,	9.2	2
258	Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. <i>Pharmacogenetics and Genomics</i> , 2021 , 31, 10-16	1.9	1
257	Molecular characterization of squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , 2021 , 12, 2423-2437	2.8	1
256	Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	4
255	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021 , 5, 95	9.8	1
254	Reprogramming CBX8-PRC1 function with a positive allosteric modulator. <i>Cell Chemical Biology</i> , 2021 ,	8.2	3
253	Novel Genomic Differences in Cell-Free Circulating DNA Profiles of Young- Versus Older-Onset Colorectal Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021 , 10, 336-341	2.2	2
252	Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. <i>Scientific Reports</i> , 2021 , 11, 5639	4.9	1
251	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1153-1160	6.1	0
250	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3234-3242	12.9	5
249	Clocking cancer: the circadian clock as a target in cancer therapy. <i>Oncogene</i> , 2021 , 40, 3187-3200	9.2	7
248	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. <i>Targeted Oncology</i> , 2021 , 16, 517-527	5	1

247	Single cell RNA-sequence analysis to identify transcriptomic differences associated with treatment outcome and ethnicity in circulating tumor cells (CTCs) from patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3041-3041	2.2	0
246	Human colorectal cancer-on-chip model to study the microenvironmental influence on early metastatic spread. <i>iScience</i> , 2021 , 24, 102509	6.1	10
245	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021 , 11, 12191	4.9	0
244	Impacts of the SARS-CoV-2 Pandemic on Young Adult Colorectal Cancer Survivors. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021 ,	2.2	2
243	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021 , 150, 133-142	7.5	1
242	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021 , 40, 4894-4905	9.2	2
241	VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer. <i>Molecular Oncology</i> , 2021 , 15, 2801-2817	7.9	1
240	The Emergence of Baricitinib: A Story of Tortoises Versus Hares. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1251-1252	11.6	1
239	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1174-1183	12.9	7
238	Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 84-95.e8	3.8	8
237	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2021 , 27, 267-275	12.9	2
236	Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. <i>Investigational New Drugs</i> , 2021 , 39, 812-820	4.3	4
235	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 2723-2733	12.9	12
234	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2021 , 21, 285-295	2.5	0
233	Evaluating the impact of age on immune checkpoint therapy biomarkers. <i>Cell Reports</i> , 2021 , 36, 109599	10.6	3
232	Microsatellite Stable Colorectal Liver Metastases-Understanding the Mechanisms of Immune Resistance. <i>JAMA Network Open</i> , 2021 , 4, e2119025	10.4	0
231	Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy. <i>Journal of Controlled Release</i> , 2021 , 336, 433-442	11.7	1
230	Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). <i>Cancer</i> , 2021 , 127, 3801-3808	6.4	1

229	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021 , 155, 73-84	7.5	3
228	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	4
227	Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2021 , 18, 317-324	3.3	0
226	Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response.. <i>Frontiers in Oncology</i> , 2021 , 11, 771173	5.3	1
225	Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance. <i>Cancers</i> , 2020 , 12,	6.6	15
224	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies 2020 , 8,		15
223	-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020 , 12,	6.6	7
222	Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases. <i>Science Advances</i> , 2020 , 6, eaba6752	14.3	13
221	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020 , 10, 9778	4.9	1
220	12-Chemokine signature, a predictor of tumor recurrence in colorectal cancer. <i>International Journal of Cancer</i> , 2020 , 147, 532-541	7.5	15
219	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020 , 121, 1320-1328	2.8	5
218	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020 , 5, e000682	6	34
217	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 757-770	19.4	82
216	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , 2020 , 12,	6.6	2
215	Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. <i>Clinical Cancer Research</i> , 2020 , 26, 4756-4766	12.9	6
214	Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. <i>Cancer Science</i> , 2020 , 111, 441-450	6.9	5
213	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020 , 46, 955-966	3.6	7
212	The heterogeneous clinical and pathological landscapes of metastatic -mutated colorectal cancer. <i>Cancer Cell International</i> , 2020 , 20, 30	6.4	22

211	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020 , 131, 89-97	7.5	3
210	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 846-854	12.9	43
209	Comprehensive molecular analysis of microsatellite-stable (MSS) tumors with high mutational burden in gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3631-3631	2.2	
208	Molecular correlates of PD-L1 expression in patients (pts) with gastroesophageal (GE) cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4558-4558	2.2	
207	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. <i>European Journal of Cancer</i> , 2020 , 133, 66-73	7.5	4
206	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, 404-413	5.7	13
205	Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. <i>Gastroenterology</i> , 2020 , 158, 1274-1286.e12	13.3	47
204	Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. <i>Molecular Therapy</i> , 2020 , 28, 536-547	11.7	56
203	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 140, 119-129	7.5	13
202	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. <i>PLoS ONE</i> , 2020 , 15, e0239439	3.7	3
201	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2634-2640	6.1	4
200	All You Need to Know About Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. <i>JCO Oncology Practice</i> , 2020 , 16, 793-798	2.3	21
199	Molecular characteristics of and mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020 , 5, e000942	6	11
198	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer 2020 , 8,		4
197	The structure-function relationship of oncogenic LMTK3. <i>Science Advances</i> , 2020 , 6,	14.3	7
196	Risk of Persistent Opioid Use following Major Surgery in Matched Samples of Patients with and without Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2126-2133	4	1
195	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020 , 26, 5943-5951	12.9	17
194	Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020 , 6, 1713-1721	13.4	13

193	Partition: a surjective mapping approach for dimensionality reduction. <i>Bioinformatics</i> , 2020 , 36, 676-681	7.2	2
192	Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. <i>International Journal of Cancer</i> , 2020 , 147, 2948-2956	7.5	32
191	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019 , 25, 7497-7505	12.9	21
190	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019 , 10, 431	17.4	45
189	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3096-3103	12.9	30
188	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019 , 51, 1113-1122	16.2	164
187	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019 , 69, 305-343	220.7	86
186	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , 2019 , 111, 138-147	7.5	3
185	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. <i>International Journal of Cancer</i> , 2019 , 145, 2082-2090	7.5	0
184	A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2019 , 145, 2450-2458	7.5	5
183	Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019 , 4, e000489	6	8
182	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019 , 109, 175-182	7.5	17
181	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019 , 24, 319-326	5.7	19
180	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. <i>European Journal of Cancer</i> , 2019 , 118, 121-130	7.5	29
179	High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. <i>PLoS ONE</i> , 2019 , 14, e0219469	3.7	3
178	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019 , 45, 139-154	8.8	19
177	The impact of panitumumab treatment on survival and quality of life in patients with wild-type metastatic colorectal cancer. <i>Cancer Management and Research</i> , 2019 , 11, 5911-5924	3.6	15
176	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , 2019 , 20, 1070-1082	21.7	101

175	Molecular insight of regorafenib treatment for colorectal cancer. <i>Cancer Treatment Reviews</i> , 2019 , 81, 101912	14.4	44
174	Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. <i>Oncotarget</i> , 2019 , 10, 7016-7030	3.3	7
173	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 564-564	2.2	
172	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3048-3048	2.2	0
171	A Multicenter Comparison of Complementary and Alternative Medicine (CAM) Discussions in Oncology Care: The Role of Time, Patient-Centeredness, and Practice Context. <i>Oncologist</i> , 2019 , 24, e1180-e1189	5.7	179
170	Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). <i>Oncologist</i> , 2019 , 24, 921-932	5.7	33
169	MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 2988-2995	12.9	31
168	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e8-e19	3.8	9
167	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2019 , 107, 100-114	7.5	5
166	Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. <i>International Journal of Cancer</i> , 2019 , 144, 2567-2577	7.5	2
165	B cell and B cell-related pathways for novel cancer treatments. <i>Cancer Treatment Reviews</i> , 2019 , 73, 10-19	14.4	59
164	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018 , 16, 805-812	6.6	114
163	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e471-e488	3.8	4
162	Outlooks on Epstein-Barr virus associated gastric cancer. <i>Cancer Treatment Reviews</i> , 2018 , 66, 15-22	14.4	74
161	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 251-266	3.5	29
160	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 500, 621-625	3.4	34
159	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e395-e414	3.8	16
158	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018 , 118, 938-946	8.7	19

157	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018 , 118, 955-965	8.7	10
156	Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. <i>Pharmacogenomics Journal</i> , 2018 , 18, 29-34	3.5	25
155	Biomarker-driven and molecular targeted therapies for colorectal cancers. <i>Seminars in Oncology</i> , 2018 , 45, 124-132	5.5	7
154	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018 , 18, 623-632	3.5	4
153	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. <i>Cancer Cell International</i> , 2018 , 18, 99	6.4	34
152	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018 , 18, 98	4.8	6
151	Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e741-e749	3.8	16
150	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. <i>Oncologist</i> , 2018 , 23, 1319-1327	5.7	61
149	Identification of a Genomic Region between and Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018 , 24, 4734-4744	12.9	8
148	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2018 , 13, e0193640	3.7	3
147	Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 215-222.e3	3.8	3
146	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12106-12106	2.2	2
145	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3576-3576	2.2	1
144	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018 , 4,	3.8	2
143	Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12098-12098	2.2	
142	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4098-4098	2.2	
141	CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. <i>Cancer Treatment Reviews</i> , 2018 , 63, 40-47	14.4	433
140	Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e121-e125	3.8	11

139	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018 , 63, 48-60	14.4	89
138	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , 2018 , 24, 784-793	12.9	14
137	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 773-779	2.2	938
136	Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 77-78	19.4	20
135	Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity. <i>Journal of the American Chemical Society</i> , 2018 , 140, 16413-16417	16.4	104
134	Management of Advanced Small Bowel Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 69	5.4	8
133	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1451-1455	8.7	14
132	Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 2788-2795	6.1	3
131	A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 1193-1198	2.7	14
130	The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. <i>Pharmacogenomics</i> , 2017 , 18, 197-200	2.6	7
129	Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017 , 28, 1015-1022	10.3	20
128	What We Know About Stage II and III Colon Cancer: It's Still Not Enough. <i>Targeted Oncology</i> , 2017 , 12, 265-275	5	21
127	VEGF Ligands 2017 , 639-658		
126	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2392-2401	27.4	434
125	Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2017 , 141, 1222-1230	7.5	14
124	Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. <i>International Journal of Cancer</i> , 2017 , 141, 383-392	7.5	5
123	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017 , 77, 13-20	7.5	15
122	Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017 , 86, 197-206	7.5	16

121	Colorectal cancer: epigenetic alterations and their clinical implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017 , 1868, 439-448	11.2	35
120	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1182-1191	21.7	1317
119	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017 , 123, 4506-4514	6.4	14
118	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1297-1308	5.4	17
117	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. <i>Annals of Oncology</i> , 2017 , 28, 2780-2785	10.3	19
116	DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. <i>Cancer</i> , 2017 , 123, 3732-3743	6.4	13
115	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017 , 17, 408	4.8	20
114	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. <i>Indian Journal of Surgical Oncology</i> , 2017 , 8, 580-590	0.7	2
113	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. <i>JAMA Oncology</i> , 2017 , 3, 194-201	13.4	409
112	Immunotherapy in Gastrointestinal Cancers. <i>BioMed Research International</i> , 2017 , 2017, 4346576	3	45
111	Genetic variations within the vitamin C transporter genes to predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11507-11507	2.2	1
110	Characterization of tumor mutation load (TML) in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11517-11517	2.2	15
109	Association of immune-related genes to neutrophil-lymphocyte ratio (NLR) with survival of cetuximab treatment for metastatic colorectal cancer (mCRC): JACCRO CC-05/06AR.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11613-11613	2.2	1
108	Primary (1 st) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3503-3503	2.2	36
107	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3505-3505	2.2	34
106	Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3510-3510	2.2	30
105	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3531-3531	2.2	24
104	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 519-519	2.2	42

103	Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3528-3528	2.2	1
102	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2814-2821	6.1	6
101	An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. <i>Clinical Cancer Research</i> , 2016 , 22, 5204-5210	12.9	11
100	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO. <i>Annals of Oncology</i> , 2016 , 27, vi152	10.3	3
99	Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment. <i>Clinical Cancer Research</i> , 2016 , 22, 3999-4004	12.9	57
98	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1740-5	6.1	7
97	Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. <i>Clinical Colorectal Cancer</i> , 2016 , 15, e221-e227	3.8	6
96	CDX2 as a Prognostic Biomarker in Colon Cancer. <i>New England Journal of Medicine</i> , 2016 , 374, 2184	59.2	12
95	A novel antimetabolite: TAS-102 for metastatic colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 355-65	3.8	7
94	TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1405-11	6.1	8
93	Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 258-9	24.2	10
92	Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 117-26	7	1
91	Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 3218-26	12.9	16
90	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016 , 114, 30-6	8.7	39
89	MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3515-3515	2.2	5
88	MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 493-493	2.2	15
87	Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. <i>Oncotarget</i> , 2016 , 7, 53668-53678	3.3	16
86	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016 , 1, e000097	6	59

85	Biomarker in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016 , 22, 156-64	2.2	31
84	The safety of monoclonal antibodies for treatment of colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 799-808	4.1	21
83	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 1091-108	3.8	8
82	Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2016 , 17, 751-9	4.6	13
81	Primary tumor location as a prognostic factor in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	298
80	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 692-700	2.2	515
79	First-line chemotherapy for mCRC: review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 607-19	19.4	106
78	Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2401-8	6.1	21
77	Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness. <i>Scientific Reports</i> , 2015 , 5, 11207	4.9	8
76	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , 2015 , 16, 937-48	21.7	240
75	IL-33 activates tumor stroma to promote intestinal polyposis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E2487-96	11.5	105
74	Multicenter Phase II Trial of Temozolomide and Bevacizumab in Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1551-6	2.2	89
73	The Molecular Taxonomy of Colorectal Cancer: What's New?. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 118-124	1	1
72	Randomized trial of TAS-102 for refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1909-19	59.2	720
71	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. <i>British Journal of Cancer</i> , 2015 , 112, 1921-8	8.7	111
70	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2374-81	6.1	3
69	Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 897-907	3.5	24
68	TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1283-92	3.5	8

67	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 2503	10.3	15
66	Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. <i>Clinical Cancer Research</i> , 2015 , 21, 5002-7	12.9	42
65	Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 43-60	3.1	24
64	Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015 , 136, 83-90	7.5	92
63	TAS-102, a novel antitumor agent: a review of the mechanism of action. <i>Cancer Treatment Reviews</i> , 2015 , 41, 777-83	14.4	80
62	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. <i>Cancer</i> , 2015 , 121, 1898-905	6.4	9
61	Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. <i>Annals of Oncology</i> , 2015 , 26, 724-730	10.3	117
60	Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECURSE trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2579-2579	2.2	9
59	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3532-3532	2.2	2
58	LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS794-TPS794	2.2	2
57	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 282-98	19.4	236
56	Molecular pathways: turning proteasomal protein degradation into a unique treatment approach. <i>Clinical Cancer Research</i> , 2014 , 20, 3064-70	12.9	11
55	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014 , 50, 57-63	7.5	136
54	A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. <i>Clinical Cancer Research</i> , 2014 , 20, 4499-4510	12.9	44
53	The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β 5. <i>Science Signaling</i> , 2014 , 7, ra58	8.8	26
52	Prospective study of EGFR intron 1 (CA) _n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. <i>Pharmacogenomics Journal</i> , 2014 , 14, 322-7	3.5	10
51	Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 528-39	6.1	27
50	ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. <i>Cell Reports</i> , 2014 , 7, 1940-55	10.6	74

49	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014 , 9, 205-14	5	22
48	Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3029-3029	2.2	3
47	Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3505-3505	2.2	38
46	Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3506-3506	2.2	32
45	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (mCRC). <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA3-LBA3	2.2	60
44	Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA444-LBA444	2.2	21
43	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013 , 381, 303-12	4 ⁰	178 ³
42	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. <i>British Journal of Cancer</i> , 2013 , 108, 2549-56	8.7	45
41	Markers of response for the antiangiogenic agent bevacizumab. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1219-30	2.2	272
40	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). <i>Annals of Oncology</i> , 2013 , 24, 2062-7	10.3	74
39	Molecular pathways: Estrogen pathway in colorectal cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 5842-8	12.9	132
38	Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'. <i>British Journal of Cancer</i> , 2013 , 109, 3129-30	8.7	2
37	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. <i>PLoS ONE</i> , 2013 , 8, e66774	3.7	55
36	Time course of regorafenib-associated adverse events in the phase III CORRECT study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 467-467	2.2	14
35	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. <i>Cancer</i> , 2012 , 118, 1523-32	6.4	32
34	Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives. <i>Scandinavian Journal of Gastroenterology</i> , 2012 , 47, 325-39	2.4	10
33	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012 , 23, 1370-1371	10.3	7
32	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 1207-1213	10.3	36

31	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 153-160	1	
30	. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 263-271	1	1
29	MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS3635-TPS3635	2.2	1
28	Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 260-260	2.2	7
27	Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA385-LBA385	2.2	25
26	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011 , 11, 247	4.8	61
25	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011 , 104, 1262-9	8.7	77
24	Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 5783-92	12.9	67
23	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 519-31	5.4	3
22	Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. <i>Clinical Cancer Research</i> , 2010 , 16, 5591-602	12.9	38
21	Colorectal cancer. <i>Lancet, The</i> , 2010 , 375, 1030-47	40	1182
20	Using The Colon Cancer Multigene Recurrence Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction?. <i>Current Colorectal Cancer Reports</i> , 2010 , 6, 183-192	1	
19	Gender disparities in metastatic colorectal cancer survival. <i>Clinical Cancer Research</i> , 2009 , 15, 6391-7	12.9	135
18	First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent. <i>Cancer Treatment Reviews</i> , 2008 , 34 Suppl 2, S3-7	14.4	73
17	Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. <i>Clinical Cancer Research</i> , 2008 , 14, 7554-63	12.9	163
16	Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. <i>Clinical Cancer Research</i> , 2008 , 14, 7884-95	12.9	102
15	Can we predict the response to epidermal growth factor receptor targeted therapy?. <i>Targeted Oncology</i> , 2008 , 3, 87-99	5	1
14	Individualization of therapy based on clinical and molecular parameters. <i>Current Colorectal Cancer Reports</i> , 2008 , 4, 193-200	1	1

13	KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 1-13, 14-6	0.6	
12	The continuum of care: a paradigm for the management of metastatic colorectal cancer. <i>Oncologist</i> , 2007 , 12, 38-50	5.7	190
11	FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3712-8	2.2	407
10	Cetuximab in the management of colorectal cancer. <i>Biologics: Targets and Therapy</i> , 2007 , 1, 77-91	4.4	12
9	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4914-21 ²		450
8	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 475-83	1.9	90
7	Pharmacogenomics and colorectal cancer. <i>Advances in Experimental Medicine and Biology</i> , 2006 , 587, 211-31	3.6	23
6	A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 319-27		263
5	Implications of genetic testing in the management of colorectal cancer. <i>Molecular Diagnosis and Therapy</i> , 2003 , 3, 73-88		9
4	ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2003 , 1, 162-6	0.6	91
3	Determinants of prognosis and response to therapy in colorectal cancer. <i>Current Oncology Reports</i> , 2001 , 3, 102-8	6.3	28
2	ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4298-304	2.2	565
1	High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach. <i>Oncogene</i> , 1997 , 15, 1481-8	9.2	21